Tech Company Financing Transactions
Altheos Funding Round
On 4/5/2010, Altheos received $20 million in Series A investment from Bay City Capital, Canaan Partners and Life Science Angels.
Transaction Overview
Company Name
Announced On
4/5/2010
Transaction Type
Venture Equity
Amount
$20,000,000
Round
Series A
Investors
Bay City Capital (Lead Investor) (Lester Kaplan)
Canaan Partners (Wende Hutton)
Novo Ventures (Peter Bisgaard)
Proceeds Purpose
The financing will be used primarily for the development of ATS907, a selective Rho-kinase inhibitor Altheos licensed from Japanese pharmaceutical company Asahi Kasei Pharma. The license also includes a series of highly active compounds (AK138 series) specifically for topical treatment for glaucoma.
Company Information
Company Status
Out of Business
Industry
Biopharmaceutical
Mailing Address
601 Gateway Blvd. 250
South San Francisco, CA 94080
USA
South San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
Altheos, Inc. is focused on the development of a best-in-class next-generation eye drop treatment for glaucoma. The lead compound, ATA907, is a selective rho-kinase (ROCK) inhibitor developed specifically for topical treatment of glaucoma which Altheos licensed from a Japanese pharmaceutical company.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Henry Hsu
Chief Medical Officer
Barbara Wirostko
Chief Scientific Officer
Ken Kengatharan
VP - Product Management
Andrew Lam
Browse more venture capital transactions:
Prev: 4/5/2010: Selecta Biosciences venture capital transaction
Next: 4/6/2010: EcoFactor venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on tech company VC transactions. VC transactions on this site are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs